EHA 2017 | Encouraging data from the RAY trial 3-year follow-up
Simon Rule
6:07
EHA 2017 | A CRISPR approach to hematological research
Sven Lundberg
2:04
EHA 2017 | Venetoclax and ibrutinib: the future for treating WM
Steven Treon
4:34
EHA 2017 | What is the focus of EHA?
Shai Izraeli
5:27
EHA 2017 | Two is better than one: drug synergy in relapsed/refractory NHL
Paul A. Hamlin
2:34
EHA 2017 | Key topics on AML at EHA 2017
Oliver Ottmann
0:52
EHA 2017 | T-cell therapy: successes and unmet needs
David Maloney
2:31
EHA 2017 | The ideal sequence: treating patients with CLL
Florence Cymbalista
2:00
EHA 2017 | What are the non-drug-related aspects of patient care?
Claire Harrison
2:19
EHA 2017 | The potential of momelotinib against myeloproliferative malignancies
Claire Harrison
0:53
EHA 2017 | NEOD001 in amyloidosis
Morie Gertz
4:16
EHA 2017 | Can a epoetin biosimilar be used to treat chemotherapy-induced anemia?
Paul Cornes
2:24
EHA 2017 | Are biosimilars as efficacious as their reference drugs?
Paul Cornes
0:52
EHA 2017 | HARMONY: a collaboration between 51 partners
Lars Bullinger
4:26
EHA 2017 | Is denosumab superior to zoledronic acid in the treatment of bone metastases in MM?
Evangelos Terpos
3:39
EHA 2017 | Novel agents for myeloma related bone disease
Evangelos Terpos
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals